Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
05.09. | Treatt appoints SkinBioTherapeutics' Manprit Randhawa as interim CFO | 3 | Alliance News | ||
15.08. | SkinBio predicts annual revenue below guidance but higher on-year | 2 | Alliance News | ||
SKINBIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
14.08. | SkinBioTherapeutics revenue rises fourfold, still misses forecasts | 2 | Sharecast | ||
14.08. | SkinBioTherapeutics - FY Trading Update | 1 | RNS | ||
30.06. | SkinBioTherapeutics - Croda Commercial Launch Progressing as Expected | 3 | RNS | ||
27.06. | SkinBioTherapeutics - Notice of IMC Shareholder Presentation | 1 | RNS | ||
20.06. | IN BRIEF: SkinBioTherapeutics raises £4 million for Superdrug deal | 2 | Alliance News | ||
20.06. | SkinBioTherapeutics - Result of WRAP Retail Offer | - | RNS | ||
16.06. | TRADING UPDATES: SkinBioTherapeutics hails 'milestone' Superdrug deal | 2 | Alliance News | ||
16.06. | SkinBioTherapeutics inks Superdrug deal, raises £4.1m | 2 | Sharecast | ||
16.06. | SkinBioTherapeutics opens retail offer to raise up to £0.62m | 1 | Investing.com | ||
16.06. | SkinBioTherapeutics - WRAP Retail Offer | - | RNS | ||
16.06. | SkinBioTherapeutics - Superdrug agreement, Placing & Retail Offer | 1 | RNS | ||
22.05. | SkinBioTherapeutics - Correction: Change of Adviser | - | RNS | ||
22.05. | SkinBioTherapeutics - Change of advisor | 1 | RNS | ||
28.04. | SkinBioTherapeutics - Warrant Exercise Notice and Total Voting Rights | 1 | RNS | ||
28.04. | SkinBioTherapeutics - Board Appointment Confirmation | 1 | RNS | ||
24.04. | SkinBioTherapeutics - Board and Leadership Changes | 1 | RNS | ||
09.04. | SkinBioTherapeutics-Aktien fallen trotz Anerkennung für Zenakine | 4 | Investing.com Deutsch | ||
09.04. | SkinBioTherapeutics shares dip despite Zenakine acclaim | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MAAT PHARMA | 4,290 | +4,38 % | MaaT Pharma Publishes Its Half Year 2025 Results and Provides a Business Update | Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall... ► Artikel lesen | |
ADMA BIOLOGICS | 14,660 | +0,89 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
QIAGEN | 39,740 | +0,68 % | Kaum Impulse für die Qiagen NV-Aktie (37,58 €) | Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 37,58 Euro. Einen minimalen Wertanstieg von 0,17 Prozent zeigt die Kurstafel für der Anteilsschein von Qiagen... ► Artikel lesen | |
CG ONCOLOGY | 39,820 | -0,09 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,480 | -0,72 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
ARVINAS | 9,610 | +3,61 % | Arvinas Inc.: Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | ||
IMMUNOME | 12,380 | +7,93 % | Where Immunome Stands With Analysts | ||
JANUX THERAPEUTICS | 24,000 | +3,05 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
ARS PHARMACEUTICALS | 10,310 | +0,29 % | ARS Pharma secures $250M loan to accelerate Neffy rollout | ||
BIONTECH | 90,45 | +0,06 % | Achtung Übernahmen! BioTechs wie Evotec, PanGenomic Health, Pfizer und BioNTech im Fokus | Die BioTech-Branche ist in Aufruhr! Mit dem Wegfall von Blockbuster-Patenten drohen kräftige Umsatzrückgänge, die strategisch kompensiert werden müssen. Angetrieben durch wirtschaftlichen Druck und... ► Artikel lesen | |
TAYSHA GENE THERAPIES | 4,770 | -2,25 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | DALLAS, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 8,470 | +13,54 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
EVOTEC | 6,744 | +2,00 % | Sonntag-Meldung zu EVOTEC SE: Jetzt zählt jede Minute! | ||
LENZ THERAPEUTICS | 48,740 | +0,87 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States | VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 65,18 | +10,89 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen |